Previous 10 | Next 10 |
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the fu...
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models WALTHAM, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a...
The following slide deck was published by Morphic Holding, Inc. in conjunction with this Read more ...
WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watc...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Noteworthy events during the week of December 22 - 28 for healthcare investors. More news on: Change Healthcare Inc., Brickell Biotech, Inc., Adaptive Biotechnologies Corporation, Healthcare stocks news, , Read more ...
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief exec...
Morphic (NASDAQ: MORF ): Q3 GAAP EPS of -$0.30 beats by $0.10 . More news on: Morphic Holding, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
MORF-720, α v β 6 -targeted oral integrin inhibitor IND now anticipated in the second half of 2020 α 4 β 7 -targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020 Morphic ends third quarter of 2019 with favorable cash, cash equivalents...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:15:05 ET RBC Capital analyst issues SECTOR PERFORM recommendation for MORF on July 9, 2024 06:29AM ET. The previous analyst recommendation was Outperform. MORF was trading at $55.74 at issue of the analyst recommendation. The overall analyst consensus : BUY...
2024-07-08 20:00:07 ET Edward Nash from Canaccord Genuity issued a price target of $57.00 for MORF on 2024-07-08 18:49:00. The adjusted price target was set to $57.00. At the time of the announcement, MORF was trading at $55.74. The overall price target consensus is at $...